placebo + cediranib

This is a combination therapy consisting of a placebo and cediranib. Cediranib is an orally active, potent small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, specifically targeting VEGFR-1, VEGFR-2, and VEGFR-3 as well as c-kit. It acts as an antiangiogenic agent by blocking the signaling pathways that promote tumor blood vessel formation. Placebo serves as an inactive comparator in clinical trials to assess the efficacy and safety of cediranib[1][5][8]. This combination is used in randomized controlled trials to evaluate the benefit of adding cediranib to standard therapies or maintenance regimens in cancer patients.